Di (2-ethylhexyl)phthalate (DEHP)

CASRN 117-81-7

  • IRIS Summary (PDF) (14 pp, 121 K)
  • Status: Di (2-ethylhexyl)phthalate (DEHP) is not being reassessed by IRIS at this time.

Health Hazard Assessments for Effects Other than Cancer


Reference Dose for Oral Exposure (RfD) (PDF) (14 pp, 121 K) last updated: 01/31/1987

RfD (mg/kg-day) System Basis PoD Composite UF Confidence
2 x10-2 Hepatic Increased relative liver weight LOAEL : 1.9 x101
mg/kg-day
1000 Medium

Reference Concentration for Inhalation Exposure (RfC) (PDF) (14 pp, 121 K)
Not assessed under the IRIS Program.

Cancer Assessment


Weight of Evidence for Cancer (PDF) (14 pp, 121 K) last updated: 09/07/1988

WOE Characterization Framework for WOE Characterization
B2 (Probable human carcinogen - based on sufficient evidence of carcinogenicity in animals) Guidelines for Carcinogen Risk Assessment (US EPA, 1986)
Basis:
  • Orally administered DEHP produced significant dose-related increases in liver tumor responses in rats and mice of both sexes.
  • This may be a synopsis of the full weight-of-evidence narrative.

Quantitative Estimate of Carcinogenic Risk from Oral Exposure (PDF) (14 pp, 121 K)

Oral Slope Factor: 1.4 x10 -2 per mg/kg-day
Drinking Water Unit Risk: 4 x10 -7 per µg/L
Extrapolation Method: Linearized multistage procedure, extra risk
Tumor site(s): Hepatic
Tumor type(s): Hepatocellular carcinoma and adenoma (NTP, 1982)


Quantitative Estimate of Carcinogenic Risk from Inhalation Exposure (PDF) (14 pp, 121 K)

Not Assessed under the IRIS Program.

You will need Adobe Reader to view some of the files on this page. See EPA’s PDF page to learn more.